A specific type of fat found in dairy called t10c12-CLA is linked to a lower chance of getting type 2 diabetes, even when accounting for how much cheese or butter someone eats.
Scientific Claim
Higher plasma concentrations of the trans-10,cis-12 conjugated linoleic acid (t10c12-CLA) isomer are associated with a 19% lower risk of developing type 2 diabetes per standard deviation increase, independent of dietary sources and other fatty acids, indicating a potential protective role distinct from other CLA isomers.
Original Statement
“Some rTFA subtypes were inversely associated with diabetes risk: ... t10c12-CLA (HR per SD 0.81; 95% CI 0.70–0.94)... t10c12-CLA remained inversely associated with diabetes risk irrespective of such adjustments.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The study design is observational, so 'associated with' is appropriate. The authors explicitly tested robustness via multiple adjustments and reported confidence intervals, avoiding causal language.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aWhether the inverse association between plasma t10c12-CLA and type 2 diabetes is reproducible across populations and measurement methods.
Whether the inverse association between plasma t10c12-CLA and type 2 diabetes is reproducible across populations and measurement methods.
What This Would Prove
Whether the inverse association between plasma t10c12-CLA and type 2 diabetes is reproducible across populations and measurement methods.
Ideal Study Design
A meta-analysis of 10+ prospective cohorts using standardized GC-MS to measure plasma t10c12-CLA at baseline, with incident type 2 diabetes confirmed by medical records, adjusting for identical covariates (BMI, diet, activity, other FAs), and stratifying by sex and metabolic health status.
Limitation: Cannot establish causation or determine if the effect is direct or mediated by other pathways.
Randomized Controlled TrialLevel 1bWhether supplementing t10c12-CLA improves insulin sensitivity or delays progression to type 2 diabetes in high-risk individuals.
Whether supplementing t10c12-CLA improves insulin sensitivity or delays progression to type 2 diabetes in high-risk individuals.
What This Would Prove
Whether supplementing t10c12-CLA improves insulin sensitivity or delays progression to type 2 diabetes in high-risk individuals.
Ideal Study Design
A double-blind RCT of 300 adults with prediabetes, randomized to 3g/day of purified t10c12-CLA or placebo for 12 months, with primary outcome of change in HOMA-IR and secondary outcomes of fasting glucose, beta-cell function (HOMA-B), and liver fat (MRI), measured at baseline, 6, and 12 months.
Limitation: Supplementation may not reflect natural dietary exposure; potential for adverse effects on lipid metabolism.
Prospective Cohort StudyLevel 2bIn EvidenceWhether the association between plasma t10c12-CLA and type 2 diabetes is consistent in a different population with similar biomarker precision.
Whether the association between plasma t10c12-CLA and type 2 diabetes is consistent in a different population with similar biomarker precision.
What This Would Prove
Whether the association between plasma t10c12-CLA and type 2 diabetes is consistent in a different population with similar biomarker precision.
Ideal Study Design
A prospective cohort study of 8,000 adults aged 40–70 in a non-European population, measuring plasma phospholipid t10c12-CLA at baseline via GC-MS, with 7-year follow-up for incident type 2 diabetes confirmed by physician diagnosis and HbA1c.
Limitation: Still observational; residual confounding possible.
Evidence from Studies
Supporting (1)
Plasma Industrial and Ruminant Trans Fatty Acids and Incident Type 2 Diabetes in the EPIC-Potsdam Cohort
Scientists measured a specific fat called t10c12-CLA in people’s blood and found those with more of it were less likely to get type 2 diabetes—even after accounting for what they ate. This matches the claim that this fat may protect against diabetes.